These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16163192)

  • 1. Adjusting the dose of low molecular weight heparins in renally impaired and obese patients.
    Spinler S
    Clin Adv Hematol Oncol; 2004 May; 2(5):270, 273-4. PubMed ID: 16163192
    [No Abstract]   [Full Text] [Related]  

  • 2. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
    Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
    Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
    Kruse MW; Lee JJ
    Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosage of enoxaparin among obese and renal impairment patients.
    Bazinet A; Almanric K; Brunet C; Turcotte I; Martineau J; Caron S; Blais N; Lalonde L
    Thromb Res; 2005; 116(1):41-50. PubMed ID: 15850607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent miscarriages: caution regarding development of clinical trials using low molecular weight heparin and pregnancy.
    Misra D; Aledort L
    Am J Hematol; 2011 Feb; 86(2):235. PubMed ID: 21264918
    [No Abstract]   [Full Text] [Related]  

  • 6. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
    Clark NP
    Thromb Res; 2008; 123 Suppl 1():S58-61. PubMed ID: 18809206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing low molecular weight heparins in kidney disease.
    Saltiel M
    J Pharm Pract; 2010 Jun; 23(3):205-9. PubMed ID: 21507815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session: the impact of the administered dose.
    Fourtounas C
    Am J Kidney Dis; 2008 Oct; 52(4):805-6; author reply 806-7. PubMed ID: 18805352
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.
    George-Phillips KL; Bungard TJ
    Pharmacotherapy; 2006 Oct; 26(10):1479-90. PubMed ID: 16999658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin.
    Busby LT; Weyman A; Rodgers GM
    Am J Hematol; 2001 May; 67(1):54-6. PubMed ID: 11279659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is establishing an appropriate bleeding risk profile in elderly patients treated with low-molecular-weight heparins needed?
    Anton E; Marti J
    J Am Geriatr Soc; 2005 Oct; 53(10):1834-5; author reply 1835-6. PubMed ID: 16181193
    [No Abstract]   [Full Text] [Related]  

  • 12. [Present opinions concerning the administration of low molecular weight heparins in hemodialysis patients].
    Drozdz M; Kowalczyk-Michałek M; Kraśniak A; Sułowicz W
    Przegl Lek; 2005; 62(4):257-9. PubMed ID: 16229247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
    Nagge J; Fernandes O; Huh J
    Am Heart J; 2005 Mar; 149(3):e21; author reply e23-4. PubMed ID: 15864222
    [No Abstract]   [Full Text] [Related]  

  • 14. Intraperitoneal and subcutaneous pharmacokinetics of low molecular weight heparin in continuous ambulatory peritoneal dialysis patients.
    Sifil A; Mermut C; Yenicerioglu Y; Cavdar C; Gumustekin M; Celik A; Yuksel F; Camsari T
    Adv Perit Dial; 2003; 19():28-30. PubMed ID: 14763030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
    Tetri S; Hakala J; Juvela S; Saloheimo P; Pyhtinen J; Rusanen H; Savolainen ER; Hillbom M
    Thromb Res; 2008; 123(2):206-12. PubMed ID: 18420258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparin administration in patients with end-stage renal disease--a comment.
    Lile J
    Pharmacotherapy; 2001 Aug; 21(8):1017; author reply 1017-9. PubMed ID: 11718492
    [No Abstract]   [Full Text] [Related]  

  • 17. Alkanoylsucroses in nasal delivery of low molecular weight heparins: in-vivo absorption and reversibility studies in rats.
    Yang T; Mustafa F; Ahsan F
    J Pharm Pharmacol; 2004 Jan; 56(1):53-60. PubMed ID: 14980001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anticoagulation with low molecular weight heparins within the framework of cardioversion for atrial fibrillation].
    Tebbe U
    Dtsch Med Wochenschr; 2007 Sep; 132(39):2033-6. PubMed ID: 17882745
    [No Abstract]   [Full Text] [Related]  

  • 19. Low-molecular-weight heparin as an adjunct to thrombolysis in ST elevation myocardial infarction.
    Quinlan DJ; Eikelboom JW
    Arch Intern Med; 2009 Jun; 169(12):1163-4. PubMed ID: 19546418
    [No Abstract]   [Full Text] [Related]  

  • 20. Pulmonary delivery of low molecular weight heparins.
    Yang T; Mustafa F; Bai S; Ahsan F
    Pharm Res; 2004 Nov; 21(11):2009-16. PubMed ID: 15587922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.